阿利西尤单抗联合阿托伐他汀钙治疗急性冠脉综合征的临床效果及对血脂水平的影响

The Clinical Efficacy of Combination Therapy with Alirocumab and Atorvastatin Calcium in the Treatment of Acute Coronary Syndrome and Its Impact on Blood Lipid Levels

目的:探讨采用阿利西尤单抗联合阿托伐他汀钙治疗急性冠脉综合征(ACS)的临床效果及对血脂水平的影响。方法:选取2022年6月—2023年9月乐平市人民医院收治的共计96例ACS患者,以随机数字表法分成研究组(n=48)与对照组(n=48),对照组给予阿托伐他汀钙治疗,研究组给予阿利西尤单抗联合阿托伐他汀钙治疗,比较两组临床疗效、血脂水平、氧化应激指标、不良反应。结果:统计治疗总有效率,研究组95.83%(46/48)较对照组81.25%(39/48)更高,差异有统计学意义(P<0.05);治疗后两组低密度脂蛋白胆固醇(LDL-C)、总胆固醇(TC)及甘油三酯(TG)水平均下降,高密度脂蛋白胆固醇(HDL-C)水平均升高,研究组LDL-C、TC、TG水平较对照组均更低,HDL-C水平更高,差异均有统计学意义(P<0.05);治疗后两组丙二醛(MDA)水平均下降,超氧化物歧化酶(SOD)水平均升高,研究组MDA水平较对照组更低,SOD水平更高,差异均有统计学意义(P<0.05);统计不良反应发生率,研究组12.50%(6/48)与对照组16.67%(8/48)比较差异无统计学意义(P>0.05)。结论:阿利西尤单抗联合阿托伐他汀钙治疗ACS,可提高临床效果,改善血脂水平,缓解氧化应激反应,安全性较高。

Objective:To explore the clinical efficacy and impact on blood lipid levels of patients with acute coronary syndrome(ACS)treated with combination therapy of Alirocumab and Atorvastatin Calcium.Method:A total of 96 ACS patients from June 2022 to September 2023 who were admitted in Leping People's Hospital were selected,and they were randomly divided into the study group(n=48)and the control group(n=48).The control group was treated with Atorvastatin Calcium,while the study group was treated with Alirocumab combined with Atorvastatin Calcium.The clinical efficacy,blood lipid levels,oxidative stress and adverse reactions in both groups were compared.Result:In the total effective rate of treatment,95.83%(46/48)in the study group was higher than 81.25%(39/48)in the control group,the difference was statistically significant(P<0.05).After treatment,the low-density lipoprotein cholesterol(LDL-C),total cholesterol(TC)and triglycerides(TG)levels in both groups were decreased,the high-density lipoprotein cholesterol(HDL-C)levels were increased,in comparision of the control group,the LDL-C,TC,and TG levels in the study group were lower,and the HDL-C level was higher,the differences were statistically significant(P<0.05).After treatment,the malondialdehyde(MDA)levels in both groups were decreased,the superoxide dismutase(SOD)levels were increased,in comparision of the control group,the MDA level in the study group was lower,and the SOD level was higher,the differences were statistically significant(P<0.05).In the incidence of adverse reactions,there was no statistically significant difference in the study group[12.50%(6/48)]and the control group[16.67%(8/48)](P>0.05).Conclusion:Alirocumab and Atorvastatin Calcium in the treatment of ACS can improve clinical efficacy,improve blood lipid levels,alleviate oxidative stress reactions,with high safety.